OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and ...

Using vedolizumab first, before tumor necrosis facor-α inhibitors, improved quality-adjusted life-years in both ulcerative ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

AbbVie today announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients.

In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical ...

Community members gathered for a different kind of walk on Saturday, looking to raise awareness for two medical conditions.

Tiny bacterial vesicles from probiotics may provide a safer way to treat gut inflammation. Could this be the next big thing ...

People of color with inflammatory bowel disease aren’t getting access to the same level of care as their white peers, a new ...

The American Gastroenterological Association (AGA) has recently released a major update to its clinical guideline for the ...

These are the symptoms of colorectal cancer. Learn about its causes, risks, and the importance of early detection.

IBS-C is a type of irritable bowel syndrome involving constipation as its main symptom. Other symptoms may include stomach ...

Pannexin 1 (PANX1) forms channels that may release signaling metabolites that are involved in a variety of pathophysiological processes, such as asthma, diabetes, hypertension or inflammatory bowel ...